Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Amphastar Pharma (NASDAQ:AMPH) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
Amphastar Pharma beat estimated earnings by 66.67%, reporting an EPS of $1.15 versus an estimate of $0.69.
Revenue was up $60.43 million from the same period last year.
Last quarter the company beat on EPS by $0.09 which was followed by a 4.29% drop in the share price the next day.
Here's a look at Amphastar Pharma's past performance:
Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
---|---|---|---|---|
EPS Estimate | 0.56 | 0.48 | 0.41 | 0.39 |
EPS Actual | 0.65 | 0.62 | 0.73 | 0.38 |
Revenue Estimate | 137.37M | 136.33M | 126.98M | 126.37M |
Revenue Actual | 145.71M | 140.02M | 135.02M | 120.13M |
To track all earnings releases for Amphastar Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AMPH